We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+9.38%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$5.45B
AUM Growth
+$30.2M
Cap. Flow
+$53.1M
Cap. Flow %
0.97%
Top 10 Hldgs %
47.61%
Holding
95
New
15
Increased
22
Reduced
33
Closed
14

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$199M
2
OSH
Oak Street Health, Inc.
OSH
+$119M
3
KYMR icon
Kymera Therapeutics
KYMR
+$83.4M
4
ANNX icon
Annexon
ANNX
+$80.8M
5
KLRS
Kalaris Therapeutics
KLRS
+$69.3M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$162M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$157M
3
BNTX icon
BioNTech
BNTX
+$132M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$64.2M
5
CYRX icon
CryoPort
CYRX
+$55M

Sector Composition

Rank Sector Weight
1 Healthcare 92.54%
2 Financials 0.5%
3 Technology 0%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
26
DELISTED
Akero Therapeutics
AKRO
$71.9M 1.32%
2,336,357
+1,944,205
+496% +$67.9M
CI icon
27
Cigna
CI
$74.5B
$67.2M 1.23%
396,693
-89,407
-18% -$15.7M
GNMK
28
DELISTED
GenMark Diagnostics, Inc
GNMK
$66.9M 1.23%
4,713,600
-189,800
-4% -$2.9M
KRYS icon
29
Krystal Biotech
KRYS
$10.5B
$64.7M 1.19%
1,501,945
+92,200
+7% +$4M
KLRS
30
Kalaris Therapeutics
KLRS
$104M
$64.2M 1.18%
+101,452
New +$69.3M
NVRO
31
DELISTED
NEVRO CORP.
NVRO
$64M 1.18%
459,609
-38,155
-8% -$5.1M
RGNX icon
32
Regenxbio
RGNX
$534M
$61.3M 1.13%
2,228,166
-8,600
-0.4% -$280K
TCRR
33
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$56.8M 1.04%
2,793,288
+1,028,100
+58% +$18.1M
APRE icon
34
Aprea Therapeutics
APRE
$8.79M
$54.6M 1%
113,436
– –
BSX icon
35
Boston Scientific
BSX
$65.4B
$54.3M 1%
1,422,049
+524,694
+58% +$20.2M
SRRK icon
36
Scholar Rock
SRRK
$6.33B
$51.3M 0.94%
2,900,889
+25,000
+0.9% +$372K
ZYME icon
37
Zymeworks
ZYME
$1.78B
$51.3M 0.94%
1,101,600
+318,100
+41% +$10.9M
NGNE icon
38
Neurogene
NGNE
$744M
$50.1M 0.92%
208,634
+6,573
+3% +$1.59M
RCEL icon
39
Avita Medical
RCEL
$157M
$44.8M 0.82%
+1,779,586
New +$44.4M
QURE icon
40
uniQure
QURE
$2.77B
$41.6M 0.76%
1,128,827
-118,308
-9% -$4.85M
AXNX
41
DELISTED
Axonics, Inc. Common Stock
AXNX
$37.8M 0.69%
741,129
-450,971
-38% -$18.8M
IMGN
42
DELISTED
Immunogen Inc
IMGN
$37.7M 0.69%
10,477,879
-1,529,100
-13% -$6.17M
BCEL
43
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$35.6M 0.65%
2,548,168
+1,556,100
+157% +$23.2M
DXCM icon
44
DexCom
DXCM
$29.6B
$34.4M 0.63%
333,648
-55,552
-14% -$5.8M
AMED
45
DELISTED
Amedisys
AMED
$33.1M 0.61%
140,180
-85,985
-38% -$19.5M
PPD
46
DELISTED
PPD, Inc. Common Stock
PPD
$31.6M 0.58%
853,092
-1,080,381
-56% -$34.2M
CLDX icon
47
Celldex Therapeutics
CLDX
$2.77B
$29.5M 0.54%
1,989,200
-10,800
-0.5% -$127K
ICUI icon
48
ICU Medical
ICUI
$3.94B
$28.9M 0.53%
158,054
-43,346
-22% -$8.16M
CTLT
49
DELISTED
CATALENT, INC.
CTLT
$28.2M 0.52%
329,419
-83,681
-20% -$7.08M
PRAH
50
DELISTED
PRA Health Sciences, Inc.
PRAH
$28.2M 0.52%
277,936
-1,400
-0.5% -$143K
1
2
3 4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q3 2020 Portfolio in Review

As of Q3 2020, Redmile Group held 95 positions worth $5.45B, up 0.56% from $5.42B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group's Q3 2020 filing shows 15 new, 22 increased, 33 reduced and 14 closed positions. Its largest new stake was Gilead Sciences: 2,869,962 shares worth $181M. The largest sale was Principia Biopharma Inc. Common Stock, an estimated $162M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials and Technology.

  • Redmile Group's largest Q3 2020 buy was Gilead Sciences: 2,869,962 shares worth $181M.
  • Redmile Group added most to Akero Therapeutics in Q3 2020, an estimated $67.9M increase.
  • Redmile Group's biggest Q3 2020 reduction was BioNTech, cutting an estimated $132M.
  • Redmile Group fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $162M.
  • Redmile Group's ten largest holdings make up 48% of its $5.45B portfolio in Q3 2020.
  • Redmile Group opened 15 new positions and closed 14 in Q3 2020.
  • Redmile Group's portfolio value rose 0.56% quarter-over-quarter to $5.45B.

Based on Redmile Group's 13F filing for Q3 2020, filed 16 Nov 2020.